New Ray Medicine FY26 H1 net loss narrows 52.2% to HK$ 3.57 million; revenue more than doubles to HK$ 113.42 million

• New Ray Medicine International Holding reported revenue of HK$ 113.42 million, more than doubled from a year earlier.
• Net loss attributable to owners narrowed 52.2% to HK$ 3.57 million, with basic and diluted loss per share at 1.78 HK cents.
• Gross profit climbed to HK$ 9.84 million, lifting gross margin to 8.68%.
• Distribution and trading revenue rose to HK$ 112.61 million, while marketing and promotion services fell to HK$ 810,000.
• Management cited higher chemical reagent sales and stronger injection drug sales; it flagged ongoing PRC volume-based procurement pressure on drug pricing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. New Ray Medicine International Holding Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260827-12303067), on August 27, 2026, and is solely responsible for the information contained therein.